KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.

Omar Albanyan, Julio Chavez, Javier Munoz

Ther Adv Hematol 13 20406207221141511

PMID36505886
PMCIDPMC9730015
DOI10.1177/20406207221141511
发表日期2022-12-12
摘要

摘要

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT) has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after frontline therapy. This approach is limited due to the intensity of chemotherapy and the proportion of patients who relapse after auto-HCT. Since the approval of anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy and novel agents, the treatment paradigm for DLBCL has changed remarkably. Anti-CD19 CAR-T therapy was first approved for relapsed DLBCL after two or more previous lines of therapy with long-lasting responses, with over 50% of patients still alive at 5-year follow-up. Here, we discuss recent randomized phase 3 clinical trials using axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in the second-line therapy setting compared with the standard of care in transplant-eligible patients who have DLBCL R/R within 12 months of completing chemo-immunotherapy, potentially changing the treatment algorithm for DLBCL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。